AKT1 and neoplasm: In an agnostic clinical trial initiated by the same investigators, it was found that patients with different tumor lineages harboring rare activating AKT1-3 mutant variants, including but not limited to activating in-dels, responded to capivasertib, broadening the list of biomarkers that predict sensitivity to ATP-competitive inhibitors [446].